The success of IMbrave150 trial in 2020 heralded a groundbreaking epoch in HCC treatment using anti PD-L1 immunotherapy (atezolizumab) synergistically intertwines with anti-angiogenic therapy (bevacizumab). The gene discussed is CD274; the disease is hepatocellular carcinoma.